| dc.contributor.author | Abet, Valentina | |
| dc.contributor.author | Filace, Fabiana | |
| dc.contributor.author | Javier, Recio | |
| dc.contributor.author | Alvarez-Builla, Julio | |
| dc.contributor.author | Burgos, Carolina | |
| dc.date.accessioned | 2024-02-05T08:38:40Z | |
| dc.date.available | 2024-02-05T08:38:40Z | |
| dc.date.issued | 2017-02-15 | |
| dc.identifier.citation | European Journal of Medicinal Chemistry 127 (2017) 810e827 | es |
| dc.identifier.issn | 0223-5234 | |
| dc.identifier.uri | https://hdl.handle.net/10115/29586 | |
| dc.description.abstract | In this review we highlight the most modern trends in the prodrug strategy. In drug research and
development, the prodrug concept has found a number of useful applications. Selected examples of this
approach are provided in this paper and they are classified according to the aim of their design. | es |
| dc.language.iso | eng | es |
| dc.publisher | ELSEVIER | es |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.subject | Prodrug | es |
| dc.subject | Carrier-linked prodrug | es |
| dc.subject | Bioprecursors | es |
| dc.title | Prodrug Approach: An Overview of Recent Cases | es |
| dc.type | info:eu-repo/semantics/review | es |
| dc.identifier.doi | 10.1016/j.ejmech.2016.10.061 | es |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional